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Abstract
Background: Improving the neuronal yield from in vitro cultivated neural progenitor cells (NPCs) is an essential
challenge in transplantation therapy in neurological disorders. In this regard, Ascorbic acid (AA) is widely used to
expand neurogenesis from NPCs in cultures although the mechanisms of its action remain unclear. Neurogenesis
from NPCs is regulated by the redox-sensitive WNT/β-catenin signaling pathway. We therefore aimed to investigate
how AA interacts with this pathway and potentiates neurogenesis.
Methods: Effects of 200 μM AA were compared with the pro-neurogenic reagent and WNT/β-catenin signaling
agonist lithium chloride (LiCl), and molecules with antioxidant activities i.e. N-acetyl-L-cysteine (NAC) and ruthenium
red (RuR), in differentiating neural progenitor ReNcell VM cells. Cells were supplemented with reagents for two periods
of treatment: a full period encompassing the whole differentiation process versus an early short period that is restricted
to the cell fate commitment stage. Intracellular redox balance and reactive oxygen species (ROS) metabolism
were examined by flow cytometry using redox and ROS sensors. Confocal microscopy was performed to assess
cell viability, neuronal yield, and levels of two proteins: Nucleoredoxin (NXN) and the WNT/β-catenin signaling
component Dishevelled 2 (DVL2). TUBB3 and MYC gene responses were evaluated by quantitative real-time PCR.
DVL2-NXN complex dissociation was measured by fluorescence resonance energy transfer (FRET).
Results: In contrast to NAC which predictably exhibited an antioxidant effect, AA treatment enhanced ROS metabolism
with no cytotoxic induction. Both drugs altered ROS levels only at the early stage of the differentiation as no changes
were held beyond the neuronal fate commitment stage. FRET studies showed that AA treatment accelerated the
redox-dependent release of the initial pool of DVL2 from its sequestration by NXN, while RuR treatment hampered
the dissociation of the two proteins. Accordingly, AA increased WNT/β-catenin signaling output i.e. MYC mRNA level,
whereas RuR attenuated it. Moreover, AA improved neurogenesis as much as LiCl as both TUBB3-positive cell yield and
TUBB3 mRNA level increased, while NAC or RuR attenuated neurogenesis. Markedly, the neurogenesis outputs between
the short and the full treatment with either NAC or AA were found unchanged, supporting our model that neuronal
yield is altered by events taking place at the early phase of differentiation.
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Conclusions: Our findings demonstrate that AA treatment elevates ROS metabolism in a non-lethal manner prior to
the NPCs commitment to their neuronal fate. Such effect stimulates the redox-sensitive DVL2 activation and WNT/β-
catenin signaling response that would enhance the ensuing neuronal cell differentiation.
Keywords: Ascorbic acid, Dishevelled, N-acetyl-L-cysteine, Neural progenitors, Neuronal differentiation, Nucleoredoxin,
Reactive oxygen species, Redox state, WNT/β-catenin signaling
Background
In the last decades, much effort has been made to over-
come issues in clinical potential application of human
central nervous system (CNS) precursors for transplant-
ation in neurological diseases [1, 2]. One potent therapy
consists in the use of in vitro expanded neural progeni-
tor cells (NPCs) [3]. Precursor cells from rat embryonic
ventral mesencephalon can be expanded in vitro and dif-
ferentiated into dopaminergic neurons whose transplant-
ation in hemiparkinsonian rats results in a functional
recovery [4]. In addition, the transplantation into Parkin-
sonian rats of human dopamine neurons derived from in
vitro expanded midbrain precursors results in successful
grafts [5]. The success of such therapies depends on the
efficiency of in vitro generation of human dopamine
neurons prior to the transplantation. Numerous reports
emphasize the critical impact of a simple supplementa-
tion of the culture medium with ascorbic acid (AA);
doses comparable to the physiologic extracellular levels
in the brain [6] facilitate the large-scale production of
dopaminergic neurons from CNS precursors ([7–18]; see
Table 1). AA is an essential nutrient widely admitted as
an antioxidant agent in vivo [19, 20], and playing a role
as cofactor in various biochemical reactions of the cell
metabolism [21]. Moreover, AA treatment not only af-
fects CNS precursor differentiation but also enhances
dopamine neuron conversion from human placenta-
derived mesenchymal stem cells [22], human blood em-
bryonic stem cells [23] or adult rat skeletal muscle-
derived stem cells [24], which suggests that AA could
participate in the lineage cell commitment.
The mechanisms by which AA enhances neuronal
differentiation of CNS precursors are still unclear. AA is
found to change the responsiveness of genes regulating
neuronal development and maturation as well as signaling
pathways implicated in cell fate determination of mam-
mal precursors [13, 15]. Importantly, AA-mediated
NPCs dopaminergic differentiation is also found ac-
companied with an up-regulation of gene products impli-
cated in reactive oxygen species (ROS) detoxification;
such an increase in expression of antioxidant response
genes has been attributed to AA pro-oxidant ability [15].
Indeed, the crucial role of ROS in the regulation of signal-
ing pathways in many aspects of cell physiology including
NPCs differentiation is well documented [25, 26].
However, the redox properties of AA are still controversial
as both pro- and antioxidant effects are reported and
mostly depend on the experimental conditions and
models of the studies (see for reviews [20, 21]). Although
no clear evidence on AA pro-oxidant effect has been pro-
vided so far in vivo, AA antioxidant role is discussed ex
vivo in rat brain slices [27, 28] and in in vitro models as
cultured human lymphocytes and lung cells [29, 30] and
solutions [29–32]. So far, no clear evidence that AA acts
as pro- or antioxidant to favor neuronal differentiation of
NPCs have been provided since direct measurements of
ROS levels are missing in all the reports stressing the posi-
tive role of AA in NPCs neurogenesis (see references in
Table 1). Considering the important role that AA plays in
the cellular metabolism, and that ROS are known to either
induce cellular damage [33] or act as messengers regulat-
ing numerous redox events in many signaling pathways
[25], elucidating the mechanisms by which AA improves
the neuronal differentiation of CNS precursors remains an
important challenge.
To address the relationship between AA effects on the
ROS levels and the neuronal differentiation of NPCs, we
used the immortalized human neural progenitor ReNcell
VM cells that have been extensively characterized the
last decade and have proved their reliability as in vitro
NPC model. These cells are reported to promptly differ-
entiate, in vitro, into glial cells and dopaminergic neu-
rons within 2–3 days upon growth factors removal [34],
and to commit to their neuronal fate within the first day
of differentiation [26, 35]. Obviously, investigating the
effects of AA implies to take into account that its acti-
vities depend on two main factors as all the pharmaco-
logical drugs. First, AA activities depend on the initial
dosage of the reagent; we focused our investigations on
the effects of the compound at the physiological relevant
dose of 200 μM [6] to stay in agreement with the con-
centration range used in the previous studies on culti-
vated CNS precursors (Table 1). Second, AA effects also
depend on its administration period that influences the
time required for the compound to accumulate within
the cells and to initiate the mechanisms implicated with
its redox activity. Accordingly, we ensured that AA
redox activity takes place during the beginning of the
differentiation phase by supplementing the reagent to
the cells 24 h prior to the differentiation was initiated
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and simultaneously with the induction of the differenti-
ation. We then compared its effects with molecules well
recognized for either their pro-neurogenic or antioxi-
dant activity.
First, to elucidate the nature and the time range of AA
redox properties we monitored the kinetics of both
intracellular redox balance and ROS metabolism. Kinet-
ics were performed from the first hours of the differenti-
ation i.e. a redox-sensitive period found to modulate the
neurogenesis [26], up to 1 day i.e. after the cell fate com-
mitment phase. Second, to verify AA effect on neuro-
genesis we quantified the neuronal yield and assessed
the gene expression level of a specific neuronal marker.
Two periods of treatment were compared to clarify
whether the neurogenic effect of AA happens during the
cell fate commitment stage and/or after cells committed
to their fate. Thus, the cell exposure to AA was either
continuous up to the third day of differentiation or
interrupted after the first day. Finally, to connect the
redox activity of AA with its neurogenic effect we inves-
tigated how the reagent influences the response of the
WNT/β-catenin signaling pathway. Since its activation is
a pre-requisite for the neuronal differentiation of
ReNcell VM cells [26, 36], and since its output is modu-
lated by ROS during the cell fate commitment period
[26, 35], we hypothesized that this pathway may play a
key role in AA effects. Here, our findings reveal that AA
treatment results in a non-lethal pro-oxidant effect in in
vitro differentiated human NPCs and that it enhances
ROS metabolism strictly during the cell fate commit-
ment period. Our data also indicate that AA treatment
enhances both the WNT/β-catenin signal transduction
and the neuronal differentiation. Finally, they show that
AA treatment facilitates the redox-sensitive dissociation
of complexes made of two proteins [26, 37]: Nucleore-
doxin (NXN) that is an endogenous antioxidant ubiqui-
tously expressed in the cells [38]; and Dishevelled segment
polarity protein 2 (DVL2), an essential upstream mediator
Table 1 Overview of reports stressing that AA ameliorates the neuronal differentiation from NPC progenitors
NPC models Differentiation factors Enhanced effects Refs.
Rat embryonic mesencephalic cell cultures 200 μM AA -Glial differentiation
-Neurite growth
-Dopamine neurons
[7]
Mouse embryonic stem cells 200 μM AA + SHH + FGF8 -Dopamine neurons
-Serotonin neurons
[8]
Long-term basic fibroblast growth factor
expanded rat mesencephalic precursors
100 μM AA -Dopamine neurons [9]
Mouse embryonic stem cells 200 μM AA + SHH + FGF8 -Dopamine neurons [10]
Nurr1-transfected rat embryonic cortical
progenitors
200 μM AA + B27 -Dopamine neurons [11]
Rat embryonic cortical precursors 200 μM AA -Astrocyte differentiation
-Neuronal differentiation
and maturation
[12]
Mouse ventral mesencephalic precursors 200 μM AA -Astrocyte differentiation
-Dopamine neurons
-Gene responses related
to cell fate determination,
neuron development and
maturation
[13]
bFGF/SHH-stimulated rat ventral
mesencephalic precursors
200 μM AA -Dopamine neurons [14]
Rat ventral mesencephalic precursors 200 μM AA -Dopamine neurons
-Gene responses related to
dopamine neuron marker,
ROS response mediators
and trophic factors
[15]
Mouse embryonic stem cells 200 μM AA + SHH + FGF8b -Dopamine neurons [16]
Rat ventral mesencephalic precursors 100 μM AA -Dopamine neurons
-Graft survival
[17]
Long-term expanded human fetal midbrain
and cortical precursor cultures
200 μM AA + low O2 + longer
diff. time
-Neuronal yield
-Dopamine neurons
[18]
AA: Ascorbic acid
SHH: Sonic hedgehog
FGF8: Fibroblast growth factor 8
bFGF: Basic fibroblast growth factor
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of the WNT/β-catenin pathway [39] which relays the sig-
nal further downstream once its initial inactive pool is re-
leased from sequestration by NXN [26]. Altogether, our
results infer that AA treatment potentiates the neuronal
fate commitment of NPCs by increasing the ROS metab-
olism which enhances the redox-dependent WNT/β-ca-
tenin signaling output. Accordingly, our study supports
the beneficial AA supplementation at physiological doses
for improving the in vitro neuronal yield of human NPCs
that are aimed at cell replacement and regenerative ther-
apies in the treatment of neuronal disorders.
Methods
Cell culture
Experiments were conducted in the immortalized hu-
man neural progenitor ReNcell VM cells derived from
the ventral midbrain of a 10-week human fetal neural
tissue (Merck Millipore, Billerica, MA, USA). Cells are
cultivated in flasks pre-coated with Cultrex Mouse Lam-
inin I (Trevigen, Gaithersburg, Germany), in proliferating
medium containing DMEM/F12 medium, B27 neural cell
supplement, L-glutamine, gentamycin, human basic fibro-
blast growth factor (all from Invitrogen, Karlsruhe,
Germany), human epidermal growth factor and heparin
(all from Sigma-Aldrich, Steinheim, Germany) as de-
scribed previously [34, 36]. When 80% cell confluence is
reached, differentiation is induced by discarding the prolif-
erating medium followed by washing steps and replace-
ment with differentiating medium i.e. medium without
growth factors.
Cell treatment
Proliferating and/or differentiating cells were treated
with 5 μM phorbol 12-myristate 13-acetate (PMA),
200 μM ascorbic acid (AA), 5 mM N-acetyl-L-cysteine
(NAC), 1 mM hydrogen peroxide (H2O2), 15 mM lith-
ium chloride (LiCl) or 0.5 μM ruthenium red (RuR) (all
from Sigma-Aldrich). Different time ranges for cell treat-
ments were applied. H2O2 or PMA were used as positive
controls for redox state and ROS detections, and were
added to untreated proliferating cells for 1 h or 24 h, re-
spectively. AA or NAC were added to untreated prolifer-
ating cells for 24 h. Then, the cell differentiation was
initiated and the AA-pre-treated- and NAC-pre-treated
cells were respectively exposed to AA or NAC for two
periods: a long period that corresponds to a drug expos-
ure along the 72 h of differentiation (i.e. full treatment);
a shorter one that consists in a drug exposure for the
first 24 h of differentiation followed by an incubation of
the cells in drug-free differentiating medium for the next
48 h (i.e. short treatment). LiCl or RuR were added to
untreated proliferating cells for 1 h. Then a further ex-
posure of the cells to LiCl for 24 h or to RuR for 2 h
was performed at the onset of the differentiation
process, followed by an incubation of the cells in drug-
free medium up to the third day of differentiation. RuR
effect was also examined for a full treatment along the
72 h of differentiation.
Flow cytometry
Intracellular redox state and ROS levels were assessed
through flow cytometry using the redox indicator 5(6)-
carboxy-2′,7′-dichlorodihydrofluorescein diacetate (car-
boxy-H2DCFDA) (Invitrogen) and the ROS indicator
dihydrorhodamine 123 (DHR123) (Sigma-Aldrich), re-
spectively [40]. Cells were stained with 10 μM carboxy-
H2DCFDA for 1 h or with 1 μM DHR123 for 0.5 h at
37 °C, 5% CO2, in the dark. After rinsing with pre-
warmed culture medium, a further incubation of the
carboxy-H2DCFDA stained-cells for 0.5 h was per-
formed to allow the diacetate group of the probe being
hydrolyzed by cellular esterases and to render the probe
sensitive to oxidation according to the manufacturer’s
instructions. Cells were then placed in HBSS comple-
mented with 14 mM HEPES and 0.9% NaCl (all from
Carl Roth, Karlsruhe, Germany) prior measurements.
Mean fluorescence intensities in a total of 104 cells were
determined in each sample using EPICS XL-MCL flow
cytometer system (Beckman Coulter). An unstained cell
sample was carried along as a control for auto-
fluorescence. Data were analyzed for 4 independent ex-
posure experiments measured in duplicates. Results are
shown as means ± SD a.u. (arbitrary units).
Immunocytochemistry
Cells grown on glass coverslips pre-coated with poly-D-
lysine then with laminin were fixed 20 min with 4%
paraformaldehyde and 4% sucrose in PBS followed by
10 min quenching with 50 mM NH4Cl and 5 min
permeabilization with 0.2% Triton-X100 (all from
Sigma-Aldrich). Non-specific binding sites were blocked
1 h with 1% gelatin (Sigma-Aldrich). Cells were incu-
bated 1 h with the following primary antibodies: mouse
anti-glial fibrillary acidic protein-Cy3-conjugate (i.e.
anti-GFAP; dilution 1:400) (Sigma-Aldrich, Cat# C9205);
mouse anti-tubulin, beta 3 class III-FITC-conjugate (i.e.
anti-TUBB3; dilution 1:80) (Abcam, Cat# ab25770);
rabbit anti-dishevelled segment polarity protein 2 (i.e.
anti-DVL2; dilution 1:200) (Santa Cruz Biotechnology,
Cat# sc-13974); goat anti-nucleoredoxin (i.e. anti-NXN;
dilution 1:200) (Santa Cruz Biotechnology, Cat# sc-
161973). When required, cells were rinsed with 0.2% gel-
atin and incubated 45 min with anti-rabbit Alexa Fluor
488 or anti-goat Alexa Fluor 594 secondary antibodies
(all from Invitrogen; dilution 1:500); then to prevent any
dissociation of the secondary antibodies an additional
post-fixation step (10 min with 2% paraformaldehyde
and 2% sucrose) was carried out, followed by a
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quenching step (5 min with 50 mM NH4Cl). Nuclei were
stained 10 min with 2 μM Hoechst 32258 (Sigma-Al-
drich). Coverslips were mounted using prolong gold
antifade reagent (Invitrogen).
Confocal microscopy and quantitative image analysis
Neuronal cell differentiation imaging was performed
using LSM 710 NLO confocal microscope system (Carl
Zeiss). Fluorescent images of DVL2 and NXN proteins
were acquired with TCS SP2 AOBS confocal laser scan-
ning microscope (Leica). The parameter settings (de-
tector gain and offset, pinhole size at 1 arbitrary unit,
laser power, confocal section, zoom factor, frame aver-
aging) were kept constant for all comparative set of ex-
periments. With these settings no photobleaching was
detected after several repeated measurements on the
same microscopic field. Brightness/contrast adjustments
were applied equally to every pixel in the images (i.e.
maximum projections), for each comparative set (e.g.
control vs. treatment) using Fiji/ImageJ. Adjustments
were performed on individual color channels before
merging images. No change to gamma settings was ap-
plied. For neuron quantitation, TUBB3-positive cells
were counted and the neuronal yield was calculated as %
of the population from the ratio between TUBB3-
positive cells and Hoechst-stained cells (i.e. whole cell
population). For quantification of protein amounts, re-
gions of interest were set for each cell in the images
based on cell boundaries and mean fluorescence inten-
sities were measured. The background fluorescence was
subtracted for each image and values were then normal-
ized. For each time point or treatment condition, at least
10 images per experiment were recorded for both
neuron counting and protein level quantification experi-
ments. Data are shown as means ± SD from 3 independ-
ent experiments.
Cell viability assay
Cell density was quantified to assess cytotoxicity follow-
ing the different treatments. For each treatment condi-
tion, proliferating cells were seeded on glass coverslips
pre-coated with poly-D-lysine and laminin at the same
cell concentration. Cell differentiation was induced up to
3 days when the cell confluency reached ~80%. Then,
cells were loaded with 2 μM Hoechst 32258 for 10 min
followed by 2 washing steps with PBS. Coverslips were
fixed and mounted as described above and images of nu-
clei were acquired with LSM 710 NLO confocal micro-
scope. Nuclei were counted using Fiji/ImageJ software to
determine the residual cell density. The nuclear labelling
reports the number of cells in the population. Cells were
treated with AA, LiCl, RuR or NAC as aforementioned.
Images were acquired for proliferating cells treated for
24 h with AA, and after 72 h of differentiation. About 10
images per experiment were captured for each condi-
tion. Data were obtained from 3 independent experi-
ments and presented as means (% of cell viability) ± SD.
Fluorescence resonance energy transfer (FRET)
FRET microscopy was performed to assess physical
binding between DVL2 and NXN proteins. FRET was
measured with the sensitized emission method [41]
using TCS SP2 AOBS confocal microscope as previously
described [26], and the parameter settings were kept
constant throughout all experiments. Different set of cell
specimens were prepared to get the fully corrected FRET
signal [42]: a FRET specimen consisting in a cell sample
labeled with both the donor (Alexa Fluor 488-labeling
DVL2) and the acceptor (Alexa Fluor 594-labeling
NXN), and from which the FRET signal can be detected;
and reference specimens labeled with the donor only
and the acceptor only to obtain calibration coefficients
required for adequate corrections of direct acceptor ex-
citation and donor emission bleed-through. The excita-
tion wavelengths were set at 488 nm and 594 nm for the
donor and the acceptor, respectively. The detection
wavelength ranges were set at 490–550 nm for the
donor to avoid leakage of acceptor fluorescence into the
donor image, and at 620–700 nm for the acceptor. The
acquisition method of the FRET signal included suitable
sequential laser switching-on to enable selective excita-
tion of one fluorophore, and meanwhile avoid the in-
appropriate excitation of the other one. Once FRET
signal was acquired and corrected, the proportion of dir-
ect protein-protein association i.e. FRET efficiency (FRE-
Teff ), was calculated using Eq. (1) [43]:
FRETeff ¼ ½BA βC ðγα βÞ=½C ð1β δÞ ð1Þ
Where A, B and C correspond to the intensities of the
donor, the FRET (i.e. acceptor indirectly excited by the
donor excitation) and the acceptor (i.e. acceptor select-
ively excited) signals, respectively, acquired from the
FRET specimen. α, γ and δ consist in the calibration fac-
tors calculated from the reference specimen labeled with
the acceptor only: α = A/C, γ = B/C, δ = A/B. β is a cali-
bration factor obtained from the specimen labeled with
the donor only: β = B/A. FRETeff were measured inside
individual cells (n = ~50 cells per time point) for every
condition. Measurements were performed for 3 inde-
pendent experiments, and results are presented as
means (% of FRETeff ) ± SD.
Quantitative real-time polymerase chain reaction (qPCR)
Total RNAs were extracted with high pure RNA isola-
tion kit (Roche, Mannheim, Germany) according to the
manufacturer’s instructions. Residual contaminating
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genomic DNA was digested by DNase I recombinant,
RNase-free (Roche). cDNA synthesis was primed with
oligo(dT)18 primers and generated from 1 μg template
RNA with M-MuLV RT using first strand cDNA syn-
thesis kit (Thermo Scientific, Karlsruhe, Germany) as
following: 5 min at 25 °C, 60 min at 37 °C and 5 min at
70 °C. Real-time PCR analysis was performed by mixing
100 ng template cDNA with TaqMan gene expression
master mix and following TaqMan gene expression
assays (all from Applied Biosystems, Darmstadt,
Germany): MYC (Hs00153408_m1); TUBB3 (Hs008
01390_s1); RPL13A (Hs04194366_g1). Contents were
transferred into 96-well PCR plates (Thermo Scientific)
as the final concentration of cDNA in each well was
5 ng/μl. Amplifications were performed using iQ5 real-
time PCR detection system (Bio-Rad) as following: 2 min
at 50 °C for activation of the Uracil-N-Glycosylase; 10 min
at 95 °C for polymerase activation; 40 repeats of two-step
cycling (15 s at 95 °C for denaturation and 1 min at 60 °C
for annealing and extension). Relative expression values
were obtained by normalizing Ct values of the tested
genes in comparison with Ct values of ribosomal protein
L13a (RPL13A, housekeeping gene) using the ΔCt
method. Each condition was assessed from 3 independent
samples in duplicate. Results are presented as fold induc-
tion means ± SD from 3 independent experiments.
Statistics
Statistical analyses were performed using two-tailed un-
paired Student’s t-test with GraphPad Prism 6. *P ≤ 0.05,
significantly different compared to the control (un-
treated proliferating cells i.e. t = 0 h of differentiation).
#P ≤ 0.05, significantly different between samples at each
time point. Data are presented as means ± SD and aver-
aged from at least 3 independent experiments.
Results
AA treatment increases the intracellular ROS levels strictly
during a narrow time range at the onset of human NPCs
differentiation
AA is reported to augment neurogenesis of mammalian
CNS precursors in vitro (Table 1); yet whether it displays
pro-oxidant or antioxidant effects remains uncertain.
We therefore addressed this issue in differentiating
ReNcell VM cells treated with the physiological dose of
200 μM of AA [6]; the cells were even pre-treated for
24 h before the induction of the differentiation to ensure
that AA redox activity can take place at the onset of the
differentiation process. We first examined the cellular
redox balance by flow cytometry during the first 3 h of
differentiation and after the cells committed to their fate
(i.e. at 24 h) with the redox indicator carboxy-
H2DCFDA [40]. Changes in the fluorescent signal level
are clearly linked to the redox balance as shown with
the increase triggered by the pro-oxidant reagent phor-
bol 12-myristate 13-acetate (PMA) [44] in proliferating
cells treated for 24 h (Fig. 1a). In untreated cells, indu-
cing the differentiation by growth factors removal led to
an increased fluorescent signal from 1 h that remained
stable up to 2 h and returned to baseline at 3 h (Fig. 1b).
These data confirm the switch in the redox state at the
early phase of human NPCs differentiation [26]. The sig-
nal even decreased below the baseline at 24 h (Fig. 1b),
indicating that the physiological metabolism of the cells
changed and corroborating that cells committed to dif-
ferent fates. Surprisingly, 24 h-pre-treatment of prolifer-
ating cells with AA did not affect the cellular redox state
as the fluorescent signal stayed at baseline (Fig. 1b; t =
0 h). Importantly, AA treatment led to a pro-oxidant ef-
fect only during the narrow time range of the first 3 h of
differentiation. The signal increased at 1 h and was 40%
higher than for untreated cells (Fig. 1b; 1.9 a.u. for AA-
treated cells vs. 1.3 a.u. for untreated cells). Then, the
Fig. 1 AA treatment alters the cellular redox balance at the onset of
differentiation. a Changes in the intracellular redox state measured
by flow cytometry in proliferating cells. Cells were treated with 5 μM
PMA (positive control). b Intracellular redox state was assessed up to
24 h after the differentiation was induced. Data are compared between
untreated differentiating cells and differentiating cells treated with
200 μM AA only up to 24 h post-differentiation. c Changes in intracellular
redox state measured in untreated differentiating cells were compared
with values obtained for differentiating cells treated with 5 mM NAC only
up to 24 h post-differentiation. n=~ 3.104 cells per time point. Values are
mean ± SD of three independent experiments. *P ≤ 0.05 compared
with untreated differentiating cells at t = 0 h; #P ≤ 0.05 between
each treatment condition at each time point; ns, non-significant
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signal decreased after 3 h in AA-treated cells but still
remained significantly higher than the baseline. After the
cell fate commitment stage, AA did not affect the redox
balance anymore as the signal at 24 h was as diminished
as the one for untreated cells. Next, we assessed the ef-
fect of the potent stoichiometric ROS scavenger N-
acetyl-L-cysteine (NAC) [45] on the NPCs. Untreated
cells were incubated with NAC only according to a time
exposure similar to AA i.e. a 24 h-pre-treatment prior to
the induction of the differentiation followed by a 24 h-
treatment at the onset of the differentiation. In this man-
ner, we promoted the intracellular supply in NAC to
ensure that its antioxidant effect happens during the ini-
tial differentiation phase. In contrast to AA treatment
(Fig. 1b), the NAC treatment displayed an antioxidant
effect as it limited the rise in the fluorescent signal oc-
curring during the onset of differentiation when com-
pared to control (Fig. 1c). Only a moderate increase of
the signal was found at 1 h though significantly lower
than for untreated cells; then the signal already returned
to the baseline from 2 h. Importantly, as seen for AA
treatment (Fig. 1b) NAC did not significantly modify the
redox balance in 24 h-treated proliferating cells (Fig. 1c;
t = 0 h) or after the cell fate commitment phase (Fig. 1c;
t = 24 h). Taken together, these data support the view
that AA leads to a pro-oxidant effect when supplied to
human NPCs in vitro.
To correlate the changes in redox balance with the re-
active oxygen species (ROS) metabolism, we measured
the overall ROS levels following AA treatment using
DHR123 [40]. Changes in the DHR123 signal reflect
changes in ROS levels as an enhanced signal resulted
from treatment of proliferating cells with hydrogen per-
oxide (H2O2) solution (Fig. 2a). The results obtained
with the ROS sensor (Fig. 2b) recapitulated the data ob-
tained through the use of the redox indicator. The fluor-
escent signal of DHR123 was significantly augmented
upon 1 h of differentiation of untreated cells. Then it
remained stable at 2 h, returned to the baseline at 3 h,
and even decreased below the baseline at 24 h (Fig. 2b).
AA treatment led to an earlier, higher and longer in-
crease in ROS levels compared to untreated cells: the
signal increased already from 0.5 h of differentiation,
remained higher and stable up to 3 h, and decreased
only later (Fig. 2b). These data clearly demonstrate that
AA induces a pro-oxidant effect in vitro during the on-
set of the differentiation of human NPCs. Additionally,
we found that AA did not affect ROS levels either dur-
ing proliferation (Fig. 2b; t = 0 h) or after the cell fate
commitment (Fig. 2b; t = 24 h), as the levels at these pe-
riods were comparable with the ones from untreated
cells. These findings corroborate the results obtained
with the redox indicator. The fact that the redox balance
and the ROS levels varied only during the first hours of
the differentiation upon AA or NAC treatments infers
that the molecular mechanisms facilitating the redox
properties of these reagents take place strictly during
this critical narrow period.
.
Pro-oxidant effect of AA treatment during the cell fate
commitment phase is involved in the increase in human
NPCs neurogenesis
As AA showed a pro-oxidant effect in vitro at the onset
of human NPCs differentiation, we wondered whether
such an effect could positively or negatively affect the
neurogenesis output. We thus examined by confocal
microscopy the cell population labelled with the spe-
cific neuronal marker Tubulin, Beta 3 Class III
(TUBB3) [46] 3 days after the differentiation was in-
duced (Fig. 3a). The neuronal yield was quantified by
counting TUBB3-positive cells (Fig. 3b). Around 11% of
the untreated cell population differentiated into neu-
rons after 3 days (Fig. 3a&b) in accordance with previ-
ous report [26]. The differentiation process did not lead
to any significant cell death as examined through the
cell viability assay (Fig. 4a&b). To demonstrate that cell
response to early stimuli (i.e. during the onset of differ-
entiation) drives the changes in the neuronal yield sev-
eral days later, we treated the cells with lithium
chloride (LiCl). LiCl is a potent glycogen synthase kin-
ase 3 beta inhibitor [47], which has been previously re-
ported to enhance WNT/β-catenin-mediated neurogenesis
from ReNcell VM cells, and so the neuronal yield [26].
Cells were treated with LiCl 1 h prior to the differentiation
was initiated, followed by a 24 h-treatment from the in-
duction of the differentiation. As anticipated LiCl
Fig. 2 AA treatment changes the intracellular ROS metabolism at
the early stage of differentiation. a Intracellular ROS levels has been
examined by flow cytometry in proliferating cells treated with 1 mM
H2O2 (positive control) for 1 h. b ROS levels were also assessed along the
first day of differentiation. Results were compared between untreated
and AA-treated differentiating cells. n = ~ 3.104 cells per time point.
Values are mean ± SD of three independent experiments. *P ≤ 0.05
compared with untreated differentiating cells at t = 0 h; #P ≤ 0.05
between each treatment condition at each time point; ns, non-significant
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treatment enhanced the neuronal amount up to 70%
after 3 days of differentiation (Fig. 3a&b; 18% of neu-
rons). Moreover, no cytotoxicity was observed up to
24 h of differentiation i.e. during the cell fate commit-
ment stage (Fig. 4a); the cell viability was however af-
fected later though the reagent was not exposed to the
cells anymore (Fig. 4a&b; ~25% and ~30% of dead cells
at 48 h and 72 h, respectively). Next, we monitored
neurogenesis ensuing the treatment of the cells with
AA for 48 h, i.e. 24 h prior to the differentiation was
initiated and during the first 24 h at the onset of the
differentiation. Then, the cells were deprived of AA for
the following 48 h (Fig. 3a; see AA short treatment). We
found that such treatment led to a pro-neurogenic effect
as effective as LiCl (Fig. 3a&b; 16% vs. 18% of neurons, re-
spectively) and in a non-lethal manner (Fig. 4a&b; AA
short treatment). Moreover, AA pre-treatment of the pro-
liferating cells for 24 h did not affect the cell number that
remained comparable with untreated proliferating cells
(Fig. 4b). We then extended the treatment period with AA
up to the third day of differentiation, i.e. 96 h-treatment in
total (Fig. 3a; see AA full treatment). Interestingly, the full
treatment resulted in a neuronal yield similar to the one
obtained during the short treatment (Fig. 3b; 16% of
neurons for both short and full treatments), and yet
without inducing any cytotoxicity (Fig. 4b). Hence, AA
enhances the neuronal yield without displaying any ef-
fects on the cell viability, and the pro-neurogenic
mechanisms of AA happen only during the early period
of the differentiation process.
We also quantified the neuronal yield resulting from
cell treatment with compounds displaying antioxidant
effects. First, we used ruthenium red (RuR); as we previ-
ously reported it reduces the Ca2+-mediated ROS metab-
olism i.e. ROS levels, by reversibly inhibiting the
mitochondrial calcium uniporter [26]. Since a full treat-
ment with RuR is highly cytotoxic (Fig. 4b; ~95% of dead
cells), we performed a short treatment at the onset of
differentiation (i.e. 3 h-treatment in total) which did not
affect the cell viability as measured daily up to the third
day of differentiation (Fig. 4a&b). RuR treatment re-
duced the neuronal amount (Fig. 3a) by 30% (Fig. 3b; 7%
of neurons). Second, cells were treated with NAC only
in the same way than AA: 24 h-pre-treatment followed
by either a 24 h- or 72 h-treatment upon the differenti-
ation. Importantly, both short and full treatments with
NAC similarly inhibited the neurogenesis (Fig. 3a&b;
~6% of neurons at 72 h). NAC treatment did not induce
Fig. 3 AA treatment promotes human NPC neurogenesis. a Confocal images of neurons (TUBB3-positive cells: green) and glial cells (GFAP-positive
cells: red) after 72 h of differentiation. The representative image panel in the figure was selected according to a comparable cell number for
each condition (n = 350 to 400 cells per microscopic field). Scale: 50 μm. b Neurons were counted and the neuronal yield was then calculated
(% of the population). Data for untreated differentiated cells were compared with cells treated for two periods of incubation with 200 μM AA
or 5 mM NAC (short treatment vs. full treatment), or with 15 mM LiCl or 0.5 μM RuR. n = ~ 3000 cells per condition. Values are mean ± SD of
three independent experiments. *P ≤ 0.05 compared with untreated differentiated cells at t = 72 h; #P ≤ 0.05 between short treatment and full
treatment for each condition; ns, non-significant
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any cytotoxic effect during the cell fate commitment
phase (Fig. 4a; see at 24 h); yet both treatment periods
led to a comparable extent in cell death later (Fig. 4a&b;
~30% of dead cells at 72 h). These results imply that ex-
tending NAC treatment beyond the cell fate commit-
ment period does not have any supplemental inhibitory
effect on neurogenesis. Furthermore, both RuR and
NAC display a reverse pattern to AA: they exert
antioxidant activities (see here Fig. 1b, and [26]) and they
negatively modulate the neurogenesis. Therefore, the data
stress the pivotal role of redox events at the early phase of
differentiation in the neuronal output of human NPCs.
To substantiate the findings obtained by microscopy,
we further examined by quantitative real-time PCR the
responsiveness of the neuronal marker TUBB3 gene in a
shorter differentiation time scale i.e. at 24 h and 48 h of
differentiation (Fig. 5). All treatments did not exceed the
first day of differentiation to ensure that any changes in
the neuronal output are connected to perturbations du-
ring the neuronal fate commitment stage only. Once the
differentiation was induced by withdrawing growth
factors, TUBB3 mRNA level was up-regulated at 48 h
(Fig. 5; 2.0-fold increase for control) confirming that
cells undergo neuronal differentiation. As positive con-
trol, 24 h-exposure of the cells to the pro-neurogenic
factor LiCl [26] already enhanced TUBB3 mRNA level
from 24 h (Fig. 5; 2.0-fold increase) to reach a 3.5-fold
increase at 48 h. In line with the microscopy data, the
short treatment with AA up-regulated TUBB3 gene re-
sponse in a comparable manner with LiCl: the mRNA
level steadily increased by 1.7-fold already at 24 h and by
3-fold at 48 h (Fig. 5). Conversely, 3 h-treatment of the
cells with the ROS metabolism inhibitor RuR at the on-
set of the differentiation prevented the rise in TUBB3
mRNA level by half at 48 h when compared with un-
treated cells (Fig. 5; 1.5-fold vs. 2.0-fold increase, re-
spectively). Therefore, our data support that the pro-
Fig. 4 AA treatment does not affect the cell viability. a Cell viability
was monitored at 0 h, 24 h and 48 h of differentiation. Cells were seeded
at the same concentration prior to any treatment or the induction
of differentiation. Prior to the differentiation was initiated, cells
were pre-treated for 1 h with 15 mM LiCl or 0.5 μM RuR, and for
24 h with 200 μM AA or 5 mM NAC. A further exposure of the cells
with each reagent was performed from the induction of the
differentiation: up to the 24 h post-differentiation (i.e. short
treatment) for LiCl, AA and NAC, and up to 2 h for RuR. Nuclei
were then stained as the nuclear labelling reports the number of
cells in the population. Confocal images of nuclei were acquired,
and nuclei were further counted to determine the remaining cell
density and to calculate the cell viability. n = ~ 500 cells per time
point and condition. Values are mean ± SD of three independent
experiments. *P ≤ 0.05 compared with untreated differentiating
cells at t = 0 h. b Cell viability was assessed in proliferating or 72 h-
differentiated cells for various treatments. Proliferating cells were
treated for 24 h with 200 μM AA. Alternatively, differentiation was
induced up to 72 h, concomitantly with distinct drug treatments:
15 mM LiCl, 200 μM AA, 5 mM NAC or 0.5 μM RuR for two periods
of incubation (short treatment vs. full treatment). n = ~ 3000 cells per
condition. Values are mean ± SD of three independent experiments.
*P≤ 0.05 compared with untreated proliferating cells
Fig. 5 AA treatment enhances the TUBB3 gene response. TUBB3
mRNA levels (fold change) were analysed by quantitative real-time
PCR at 0, 24 and 48 h after the differentiation was initiated. Results
for untreated cells were compared with cells treated with 15 mM
LiCl, 200 μM AA (short treatment) or 0.5 μM RuR. Values are
mean ± SD of three independent experiments. *P ≤ 0.05 compared
with untreated differentiating cells at t = 0 h; #P ≤ 0.05 between each
treatment condition at t = 48 h; ns, non-significant
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oxidant effect of AA is instrumental during the cell fate
commitment phase for improving the neuronal differen-
tiation of human NPCs.
AA treatment stimulates the WNT/β-catenin signal
transduction and the redox-sensitive DVL2-NXN complex
dissociation during the cell fate commitment phase
The neuronal commitment of human NPCs depends on
the WNT/β-catenin signaling output that can be regu-
lated from the first hours of differentiation by redox-
sensitive events [26]. We therefore wondered whether
AA pro-oxidant effect at the onset of the differentiation
may alter the response of WNT/β-catenin pathway tar-
get genes. We then assessed the expression level of v-
myc avian myelocytomatosis viral oncogene homolog
(MYC) gene [48]. Since MYC expression has been re-
ported to regulate the neuronal differentiation process of
ReNcell VM cells [36], its expression level reflects both
the neurogenesis and the WNT/β-catenin pathway out-
puts. Consistent with previous report [36], we found an
up-regulation of MYC mRNA level 48 h after the differ-
entiation was induced in untreated cells (Fig. 6; 2.5-fold
increase). Moreover, incubating the cells along the first
day of differentiation with the WNT/β-catenin pathway
stimulator LiCl [47] predictably enhanced MYC gene re-
sponse to high levels at both 24 h and 48 h post-
differentiation (Fig. 6; 10-fold and 15-fold increases,
respectively). Importantly, exposure of the cells to AA
up to the first day of differentiation (i.e. short treatment)
also led to an up-regulation of MYC gene expression. A
significant increase of the mRNA level up to 2-fold was
found at 24 h and to 3-fold at 48 h (Fig. 6). In contrast,
treatment with RuR limited the rise in MYC gene re-
sponse as the mRNA level increased only to 1.7-fold at
48 h (Fig. 6). Altogether, these findings support the idea
that the pro-neurogenic effect of AA is connected to
both the pro-oxidant effect of the reagent during the
neuronal fate commitment phase and the stimulation of
early redox-dependent events altering WNT/β-catenin
signaling response.
Nucleoredoxin (NXN) is an endogenous antioxidant
[38] sequestering the WNT/β-catenin signaling key
component Dishevelled segment polarity protein 2
(DVL2) [37, 39]. The release of the initial pool of DVL2
at the early stage of the differentiation is a redox-
sensitive step required for relaying the WNT signal to
downstream effectors [26]. Accordingly, we examined
whether the early changes in ROS metabolism resulting
from AA treatment may impact on DVL2 release from
NXN. DVL2-NXN complex dissociation was measured
by fluorescence resonance energy transfer (FRET) mi-
croscopy (Fig. 7a), and FRET efficiencies (FRETeff ) were
quantified in proliferating cells and during the first 4 h
of differentiation (Fig. 7b&c). To confirm that changes
in FRETeff solely depend in ROS levels, we treated pro-
liferating cells for 1 h with 1 mM H2O2 to enhance the
intracellular ROS concentration. FRETeff strongly de-
creased to 10-fold compared to untreated proliferating
cells (Fig. 7a&b; ctl vs. H2O2), indicating a DVL2-NXN
complex dissociation. Furthermore, we substantiated
that FRETeff reduction did not result from any dimin-
ishing protein quantities since both DVL2 and NXN
amounts increased after H2O2 treatment as quantified
by fluorescence imaging (Additional file 1: Figure S1).
We then monitored FRETeff during the first hours of
differentiation of untreated cells. FRETeff significantly
diminished by 1.9-fold at 1 h of differentiation and by
5-fold at 2 h (Fig. 7a&c). After 2 h, FRETeff values
remained low (Fig. 7a&c; ~10-fold decrease at 3 h and
4 h). Although variations of both DVL2 and NXN
amounts were held during this narrow time range
(Additional file 1: Figure S1), they are not correlated
with the changes in FRETeff, and so they did not inter-
fere with FRETeff values: from 1 h to 2 h of differen-
tiation both proteins showed elevated levels while
FRETeff values decreased; the next 2 h the protein
amounts returned to baseline while FRETeff remained
unchanged. In accordance with our previous study [26],
the reduction in FRETeff values is instead temporally
correlated with the rise in ROS metabolism observed at
the early stage of differentiation (see Fig. 2b): FRETeff
Fig. 6 AA treatment stimulates the expression of the WNT/β-catenin
signaling target gene MYC. MYC mRNA levels (fold change) were
evaluated by quantitative real-time PCR at 0, 24 and 48 h after the
differentiation was induced. Data for untreated cells were compared
with cells treated with 15 mM LiCl, 200 μM AA (short treatment) or
0.5 μM RuR. Values are mean ± SD of three independent experiments.
*P≤ 0.05 compared with untreated differentiating cells at t = 0 h; #P≤
0.05 between each treatment condition at t = 48 h; ns, non-significant
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started to decrease at 1 h when ROS levels significantly
increased, and the strongest reduction of the FRETeff
value happened at 3 h when the highest levels of ROS
were reached and maintained in a plateau. Though
ROS levels returned at baseline at 4 h, FRETeff still
remained at its lowest value indicating that both pro-
teins do not reassociate anymore; the cells do no longer
maintain high ROS metabolism for promoting DVL2
release as the protein complexes were already fully dis-
sociated [26].
Next, we examined whether AA treatment alters the
redox-sensitive DVL2-NXN dissociation. Strikingly, we
found that changes in FRETeff correlates with the varia-
tions in ROS metabolism mediated by the treatment.
Neither ROS levels (see Fig. 2b) nor FRETeff varied in
spite of the 24 h-pre-treatment with AA prior to the in-
duction of differentiation (Fig. 7a&c; t = 0 h, ctl vs. AA).
However, FRETeff decreased by 3.3 fold from 0.5 h of dif-
ferentiation i.e. simultaneously with the beginning of the
rise in ROS metabolism resulting from AA treatment; a
Fig. 7 Elevated ROS metabolism mediated by AA treatment facilitates DVL2-NXN complex dissociation. a Representative pseudocolor images of
FRETeff between DVL2 and NXN proteins obtained at 0 h, 0.5 h, 1 h and 3 h after the differentiation was initiated. Images were acquired in
untreated differentiating cells and compared with proliferating cells treated with 1 mM H2O2, and with differentiating cells treated with 200 μM
AA or 0.5 μM RuR. The colour scale at the right of the panel is shown in %. Scale: 10 μm. b FRETeff values were averaged and compared between
untreated- and H2O2-treated proliferating cells. c Mean values of FRETeff were also calculated at 0 h, 0.5 h, 1 h, 2 h, 3 h and 4 h of differentiation
for untreated- and AA- or RuR-treated differentiating cells (n = ~ 50 cells per time point and condition). Values are means (% of FRETeff) ± SD of
three independent experiments. *P ≤ 0.05 compared with untreated differentiating cells at t = 0 h; #P ≤ 0.05 each treatment condition at each
time point; ns, non-significant
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maximum FRETeff reduction by ~10 fold was already
reached at 1 h (Fig. 7a&c). Here again, the FRETeff re-
duction did not result from any diminution in the pro-
tein amounts as they rather increased at 0.5 h
(Additional file 1: Figure S1). Therefore, AA treatment
accelerated the DVL2-NXN complex dissociation just
as it did for ROS production. Conversely, inhibiting
ROS metabolism prevented the complex dissociation as
shown in RuR-treated cells (Fig. 7a&c; ctl vs. RuR).
FRETeff remained unaltered up to 2 h of differentiation;
it started to decrease only from 3 h (Fig. 7a&c; 1.6 fold-
reduction) i.e. when RuR antioxidant effect was allevi-
ated since we stopped the cell exposure to the drug
[26]. As the protein quantities augmented at 3 h instead
of being diminished (Additional file 1: Figure S1), it is
unlikely that protein amounts interfered with FRETeff
values. Changes in FRETeff can solely be ascribed to the
variations in ROS metabolism mediated by each treat-
ment. Accordingly, these data corroborate that the re-
lease of DVL2 from its complex with NXN is positively
regulated by ROS levels. Moreover, they show that the
elevated ROS metabolism mediated by AA treatment
prior to the cell fate decision facilitates the release of
the initial protein pool of the WNT/β-catenin signaling
mediator DVL2.
Discussion
In this study, we aimed to unravel whether and how AA
redox property is involved in the well recognized pro-
neurogenic effect of the reagent when supplemented at
physiological doses to NPCs. Consistent with previous
reports from mouse and rat progenitors [7–17], we show
here that treating differentiating human NPCs (i.e.
ReNcell VM cells) with AA at a physiological dose [6]
stimulates their neurogenesis in vitro (Fig. 3 and 5). Yet
evidence of AA effect on redox state during neuronal
differentiation of NPCs have been lacking so far [7–18].
Our study provides direct measures of intracellular ROS
levels (Fig. 1 and 2) and reveals that the positive regula-
tion of the neurogenesis of human NPCs by AA is ac-
companied by a pro-oxidant effect mediated by the reagent
during the cell fate commitment phase. Although our find-
ings contrast with the in vivo AA antioxidant activity, one
has to emphasize that many investigations support a pro-
oxidant effect ex vivo [27, 28] and in vitro [29–32]. Fur-
thermore, a few studies performed in cultured rodent
progenitor cells corroborate that AA acts as pro-oxidant.
First, Yu DH, et al., [15] showed that AA-mediated dopa-
minergic differentiation of rat mesencephalic precursors is
accompanied with an up-regulation of gene products that
protect against oxidative damages. Although no direct
assessment of ROS levels has been performed, the authors
attributed the rise in the antioxidant defense to a cellular
response to AA pro-oxidant properties. Second, Bartsch C,
et al., [49] reported that AA treatment of mouse embryonic
stem cells increases ROS levels and stimulates the
cardiomyogenesis.
Furthermore, we report that the positive regulation of
the neuronal differentiation of human NPCs by AA is
independent of any effects on cell viability. The effect
of AA treatment on NPCs neurogenesis and viability
was compared to the treatments with the pro-
neurogenic reagent LiCl [26] and the antioxidant NAC
[45]. Several studies emphasized the therapeutical po-
tential of LiCl in cell replacement therapies for CNS re-
generation [50–52]. Our data corroborate these previous
reports; LiCl enhances neurogenesis in our cell model as
shown by the increases of both the expression of the neur-
onal marker TUBB3 gene from 24 h (Fig. 5) and the neur-
onal amount quantified at 72 h by microscopy (Fig. 3).
LiCl treatment did not display any cytotoxic effect during
the cell fate commitment period i.e. the first 24 h; yet it
led to cell death later (Fig. 4). Of note, LiCl cytotoxicity
has been reported for comparable dose ranges and expos-
ition times of the drug in various cell types [53, 54]. More-
over, it is unlikely that the increased quantity of neurons
measured at 3 days following the treatment mainly re-
sulted from a toxicity affecting selectively the non-
neuronal cells; it has been reported that cytotoxic doses of
LiCl impaired without distinction both neuronal and glial
cell subpopulations differentiated from rat neural progeni-
tors [50]. As for NAC, it led to a late cytotoxicity compar-
able with LiCl although the antioxidant induced an
opposite effect on neurogenesis. Such a cytotoxic effect of
the reagent is known for long-term treatments with milli-
molar doses [55–57]. Conversely, AA enhances the neur-
onal yield as much as LiCl but in a non-lethal manner,
though these findings contrast with studies reporting that
AA promotes cytotoxicity in vitro [27, 28, 58]. Given that
AA treatment increases ROS metabolism, one could have
anticipated a rise in cell damage and death resulting from
an excessive ROS production [33]. However, whatever the
exposure duration (short- vs. long treatment) the physio-
logical dose of 200 μM of AA is not cytotoxic in our study,
making it unlikely that AA mediated a ROS generation
sufficient to induce an oxidative stress. One could then
wonder whether the non-lethal moderate increase in the
intracellular production of ROS mediated by AA treat-
ment may rather act as messengers regulating redox-
dependent events [25] which positively influence human
NPCs neurogenesis.
Our earlier investigations in ReNcell VM cells revealed
that the first hours of differentiation are crucial in the
regulation of the neuronal output as this early period
happens prior to the neuronal fate commitment [26, 35].
In addition, we previously demonstrated that changes in
ROS metabolic cues are endogenously induced during a
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tight timing occurring right from the first hours upon
the initiation of neuronal differentiation of the cells
[26, 35]. The physiologic switch in ROS metabolism
was found to modulate the response amplitude of the
WNT/β-catenin pathway via the control of the activ-
ity of the redox-sensitive target NXN, an ubiquitous
antioxidant [38] that sequestrates the WNT/β-catenin
signaling downstream effector DVL2 [26]. In ReNcell
VM cells the WNT/β-catenin pathway has been found
to regulate the neuronal differentiation [36], and the
early modulation of this pathway by ROS has been
shown to further alter the neuronal commitment of
the cells [26]. Remarkably, our current data unravel
that AA pro-oxidant effect strictly takes place during
the first hours of differentiation. Moreover, it has
been reported that AA treatment down-regulates the
expression of the glycogen synthase kinase 3 beta
gene during neuronal differentiation of rat precursors
[15] suggesting that AA may influence WNT/β-ca-
tenin pathway output. Taking all of these observations
together, we reasoned that both AA pro-neurogenic
and pro-oxidant effects may be connected together
through the stimulation of the redox-sensitive WNT/
β-catenin pathway, which subsequently could alter the
neuronal differentiation of human NPCs. Our current
findings show that the inhibition of ROS metabolism
by antioxidants reduces both the WNT/β-catenin sig-
naling output i.e. MYC gene expression (Fig. 6) and
the neurogenesis (Fig. 3 and 5). Conversely, AA en-
hances the WNT/β-catenin signaling response and the
neuronal yield. Importantly, one has to point out that
changes in the magnitudes of both the WNT/β-catenin
signaling response and the neurogenesis are solely linked
to the alterations of the ROS metabolism prior to the
neuronal fate commitment. First, beyond the cell fate
commitment phase (i.e. at 24-h post-differentiation), nei-
ther NAC nor AA treatments affect the intracellular ROS
metabolism as the levels are similar to untreated diffe-
rentiated cells. Second, full treatments (i.e. up to 72-h
post-differentiation) with either NAC or AA modify the
neuronal yields similarly to short treatments (i.e. up to 24-
h post-differentiation).
By which mechanism the ROS production mediated by
AA treatment may interfere with the WNT/β-catenin
pathway and so the neurogenesis? Interestingly, our data
indicate that the variations in the WNT/β-catenin sig-
naling outputs are related to the extent in the ROS-
dependent dissociation of DVL2-NXN complexes at the
beginning of the differentiation process. We previously
reported that during the proliferation of human NPCs
an initial pool of DVL2 is kept inactive as the proteins
bind to NXN molecules [26]. Once ROS metabolism in-
creases at the onset of the differentiation, DVL2 proteins
dissociate from NXN, and thus are activated and
recruited in the signaling cascade for relaying down-
stream the signal [26]. In line with this previous report,
we corroborate by FRET microscopy that the protein
complex dissociation is temporally correlated to ROS
metabolism at the onset of the human NPCs differenti-
ation (compare Fig. 2 vs Fig. 7). In addition, we demon-
strate that the extent of DVL2 release is regulated by the
amplitude and the promptness of the ROS production: a
delayed and low DVL2 dissociation resulted from the in-
hibition of mitochondrial ROS formation mediated by
the early and punctual RuR treatment (Fig. 7 and [26]);
in contrast, a strong DVL2 release followed the treat-
ment of proliferating cells with the pro-oxidant reagent
H2O2 (Fig. 7 and [37]). As for AA, we reveal that the ini-
tial inactive pool of sequestered DVL2 promptly dissoci-
ates as a result of the early and high increase in ROS
metabolism following the treatment. The dissociation of
the totality of the protein complexes happens quickly in
response to the maintaining of high ROS levels. Next,
the proteins do not form complexes anymore despite
their intracellular accumulation and further de novo syn-
thesis (Additional file 1: Figure S1 and [26]); NXN are
rather implicated in detoxifying ROS. No protein re-
association occurs even after the ROS metabolism
returned to baseline. Once released, DVL2 proteins be-
come active and commit to the WNT/β-catenin signal-
ing cascade [26]. DVL2 release tunes the extent of the
WNT/β-catenin signal transduction; in other words, the
earlier the initial pool of DVL2 is released and activated
during the cell fate commitment stage, the more efficient
and sustained is the signal [26]. Accordingly, the ele-
vated ROS metabolism mediated by AA treatment prior
to the cell fate decision facilitates DVL2 activation, and
so ameliorates the efficiency of the WNT/β-catenin sig-
nal transduction; this leads to an enhanced expression of
target genes e.g. MYC and TUBB3 [36], that finally re-
sults in an augmented neuronal yield.
The molecular mechanisms by which AA increases
intracellular ROS formation in our in vitro human NPCs
model have not been thoroughly investigated here. In
this study, we focused on the concentration of 200 μM
since this physiological dose has been mostly used in the
reports emphasizing a positive role of AA in NPCs
neurogenesis; one should therefore cautiously consider
that the mechanisms implicated in AA-mediated ROS
depend on the dose of the compound. One could how-
ever suggest a mechanism involving redox reactions
resulting from AA conversion to substrates. It has been
reported that AA pro-oxidant effect results from its
extracellular oxidation to dehydroascorbate that is trans-
ported in the cells and further reduced back to ascorbate
[59]. However, since these reactions also lead to cell
death [27, 28] such a mechanism may be unlikely in
ReNcell VM cells, as AA did not alter their viability.
Rharass et al. Journal of Biomedical Science  (2017) 24:78 Page 13 of 16
Another conceivable mechanism may implicate AA
interaction with transition metal ions although conflict-
ing studies are reported. First, such interactions either
increase [31, 32] or decrease the ROS production [20].
Next, both pro- and antioxidant effects happen simul-
taneously but in distinct compartments, i.e. respectively
in intracellular and extracellular compartments [29].
Finally, AA-mediated ROS production is found inde-
pendent from any interactions with transition metal ions
[27, 28]. Thus, further studies are needed to elucidate
how physiological doses of AA mediate ROS generation
in our cells. As this was observed only during the cell
fate commitment period, one could suggest that the mo-
lecular machinery required for this process may depend
on the cellular differentiation and metabolic stage of the
NPCs. Such molecular machinery may be efficient in
cells at the early stage of differentiation, but neither dur-
ing the proliferation stage nor in partially or terminally
differentiated cells.
To date, besides the pro-oxidant effect of AA treat-
ment demonstrated in this study, a few more potential
mechanisms have been previously proposed to explain
AA pro-neurogenic effects. Considering findings indi-
cating that AA protects cells from apoptosis [60] and
that dopamine auto-oxidation causes neuronal damages
[58], one could speculate that AA antioxidant property
might protect neurons from dopamine-mediated cyto-
toxic effect. Such a hypothesis is however questionable.
First, many investigations challenge AA antioxidant
properties [27–32]. Second, AA is also reported either
potentiating the dopamine-mediated neurotoxicity [58]
or failing to expand dopaminergic differentiation at
doses preventing a potential dopamine auto-oxidation
[9]. A more likely additional mechanism that can be at-
tributed to AA treatment involves the stimulation of
the extracellular matrix assembly needed for the devel-
opment of nervous system [61]. Such mechanism is
consistent with findings from Shin DM, et al., [13]
showing that AA treatment up-regulates the expression
of genes encoding for the extracellular membrane-
associated protein pleiotrophin and the extracellular
matrix glycoprotein vitronectin during the neuronal
differentiation of mouse precursors. Furthermore, Yu
DH, et al., [15] report an up-regulation of the expres-
sion levels of procollagen genes in neurons differenti-
ated from cultured rat precursors treated with AA.
Therefore, we do not exclude that AA pro-neurogenic
effect in human NPCs can rely on other activities of the
reagent in addition to its pro-oxidant effect. Actually, it
is likely that both AA mechanisms i.e. ROS-mediated
signaling and extracellular matrix remodeling, can act
in concert to positively modulate NPCs neurogenesis as
it is well-accepted that extracellular matrix interacts
with signaling pathways [62].
Conclusions
Our study reveals that the beneficial role of AA treat-
ment in the neuronal differentiation of human NPCs re-
sults from its non-lethal pro-oxidant effect. Moreover,
our findings are consistent with studies performed in ro-
dent precursors showing that AA stimulates expression
of genes involved in neuronal development and matur-
ation, as well as gene responsiveness for products impli-
cated in signaling pathways that control the neuronal
cell fate determination [13, 15]. Here, we demonstrate in
human NPCs that increased ROS metabolic cues follow-
ing AA treatment are strictly anchored to a period prior
to the neuronal fate commitment. Such elevated ROS
metabolism promotes DVL2 activation by facilitating the
dissociation of the initial inactivated pool of the proteins
from NXN sequestration. As a result, the WNT/β-ca-
tenin signal transduction is ameliorated and enhances
neurogenic gene expression that stimulates the decision
of the cells to commit to their neuronal fate. Our find-
ings also point out the substantial role of the redox bal-
ance in in vitro cultured NPCs for improving the
neuronal yield necessary for transplantation in regenera-
tive therapies. Finally, they emphasize the importance to
control carefully the experimental conditions including
the compounds in the cell culture media as previously
suggested [63].
Additional files
Additional file 1: Figure S1. Changes in DVL2 and NXN protein amounts
do not correlate with variations in FRETeff. Confocal images of DVL2 (a)
and NXN proteins (b) were acquired in proliferating and differentiating
cells treated or not with 200 μM AA, 0.5 μM RuR or 1 mM H2O2. Mean
fluorescence intensities were then quantified at 0 h, 0.5 h, 1 h, 2 h, 3 h
and 4 h of differentiation for each protein (see respective bar graphs).
These data demonstrate that decreases in FRETeff values (see Fig. 7) do
not result from any reduction in protein amounts which rather increase
when DVL2-NXN complexes begin to dissociate. Scale: 10 μm. n = ~ 50
cells per time point and condition. Values are means ± SD of three
independent experiments. *P≤ 0.05 compared with untreated differentiating
cells at t = 0 h; #P≤ 0.05 each treatment condition at each time point; ns,
non-significant. (JPEG 5532 kb)
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